Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 15/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5295589 | 0.92 | ADRB2 (0.58) | ADRB2ADRB3ADRB1 | |
| SCHEMBL5285332 | 0.92 | ADRB2 (0.56) | ADRB2ADRB3ADRB1 | |
| SCHEMBL5287201 | 0.88 | ADRB2 (0.54) | ADRB2ADRB3ADRB1 | |
| SCHEMBL925832 | 0.88 | ADRB2 (0.63) | ADRB2ADRB3ADRB1 | |
| SCHEMBL925503 | 0.87 | ADRB2 (0.61) | ADRB2ADRB3ADRB1 | |
| SCHEMBL5280758 | 0.86 | ADRB2 (0.50) | ADRB2ADRB3ADRB1 | |
| SCHEMBL2580435 | 0.85 | ADRB2 (0.60) | ADRB2ADRB3ADRB1 | |
| SCHEMBL5284540 | 0.85 | ADRB2 (0.54) | ADRB2ADRB3ADRB1 | |
| SCHEMBL2202730 | 0.84 | ADRB2 (0.58) | ADRB2ADRB3ADRB1 | |
| SCHEMBL2207539 | 0.84 | ADRB2 (0.58) | ADRB2ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497261-B1 | PHENETHANOLAMINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-7271197-B2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 2007-09-18 | — | — | US | disclosed |
| US-20050256201-A1 | Phenethanolamine derivatives | GLAXO GROUP LIMITED | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256201-A1 | Phenethanolamine derivatives | PNMT, PHOSPHO1, NAPEPLD | ADRB2 85/4885ADRB3 67/4885ADRB1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.